Found 6 matching trials
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease PHASE2 The purpose of this study is to evaluate the efficacy of GSK2269557 adminis...
Show More Location
GSK Investigational Site
Learn More & Join Trial
A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma PHASE2 This study is a multi-centre, randomised, double-blind, placebo-controlled ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557 PHASE1 The study will comprise three Parts:
Part A will consist of two cohorts of...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects PHASE1 GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kina...
Show More Location
GSK Investigational Site
Learn More & Join Trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients PHASE2 This is a randomised, double-blind, placebo controlled, parallel group stud...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects PHASE1 GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kina...
Show More Location
GSK Investigational Site
Learn More & Join Trial